IGEA Pharma NV
F:3B5

Watchlist Manager
IGEA Pharma NV Logo
IGEA Pharma NV
F:3B5
Watchlist
Price: 16.791 EUR -3.07%
Market Cap: 10.6m EUR

IGEA Pharma NV
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

IGEA Pharma NV
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
IGEA Pharma NV
SIX:IGPH
Operating Income
-€9.2m
CAGR 3-Years
-76%
CAGR 5-Years
-90%
CAGR 10-Years
N/A
O
ONWARD Medical NV
XBRU:ONWD
Operating Income
-€35m
CAGR 3-Years
-7%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
No Stocks Found

IGEA Pharma NV
Glance View

Market Cap
10.6m EUR
Industry
Health Care

IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.

3B5 Intrinsic Value
Not Available

See Also

What is IGEA Pharma NV's Operating Income?
Operating Income
-9.2m EUR

Based on the financial report for Dec 31, 2022, IGEA Pharma NV's Operating Income amounts to -9.2m EUR.

What is IGEA Pharma NV's Operating Income growth rate?
Operating Income CAGR 5Y
-90%

Over the last year, the Operating Income growth was -705%. The average annual Operating Income growth rates for IGEA Pharma NV have been -76% over the past three years , -90% over the past five years .

Back to Top